Characteristics of subjective cognitive decline associated with amyloid positivity

PREVENT-AD research group; for the Alzheimer's Disease Neuroimaging Initiative; FACEHBI study group

doi:10.1002/alz.12512

Characteristics of subjective cognitive decline associated with amyloid positivity

PREVENT-AD research group, for the Alzheimer's Disease Neuroimaging Initiative, FACEHBI study group

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. Results: Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Discussion: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.

Original language	English (US)
Pages (from-to)	1832-1845
Number of pages	14
Journal	Alzheimer's and Dementia
Volume	18
Issue number	10
DOIs	https://doi.org/10.1002/alz.12512
State	Published - Oct 2022
Externally published	Yes

Keywords

Alzheimer's disease
amyloid
cerebrospinal fluid
positron emission tomography
subjective cognitive decline

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Cellular and Molecular Neuroscience
Psychiatry and Mental health

Access to Document

10.1002/alz.12512

Cite this

@article{cd1513241eae4a81b97558a08ba001b2,

title = "Characteristics of subjective cognitive decline associated with amyloid positivity",

abstract = "Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. Results: Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Discussion: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.",

keywords = "Alzheimer's disease, amyloid, cerebrospinal fluid, positron emission tomography, subjective cognitive decline",

author = "{PREVENT-AD research group} and {for the Alzheimer's Disease Neuroimaging Initiative} and {FACEHBI study group} and Olin Janssen and Jansen, {Willemijn J.} and Vos, {Stephanie J.B.} and Merce Boada and Lucilla Parnetti and Tomasz Gabryelewicz and Tormod Fladby and Molinuevo, {Jos{\'e} Luis} and Sylvia Villeneuve and Jakub Hort and St{\'e}phane Epelbaum and Alberto Lle{\'o} and Sebastiaan Engelborghs and {van der Flier}, {Wiesje M.} and Susan Landau and Julius Popp and Anders Wallin and Philip Scheltens and Rikkert, {Marcel Olde} and Snyder, {Peter J.} and Chris Rowe and Ga{\"e}l Ch{\'e}telat and Agustin Ru{\'i}z and Marta Marqui{\'e} and Elena Chipi and Steffen Wolfsgruber and Michael Heneka and Henning Boecker and Oliver Peters and Jonas Jarholm and Lorena Rami and Adri{\`a} Tort-Merino and Binette, {Alexa Pichet} and Judes Poirier and Pedro Rosa-Neto and Jiri Cerman and Bruno Dubois and Marc Teichmann and Daniel Alcolea and Juan Fortea and S{\'a}nchez-Saudin{\'o}s, {M. Bel{\'e}n} and Jarith Ebenau and Cornelia Pocnet and Marie Eckerstr{\"o}m and Louisa Thompson and Victor Villemagne and Rachel Buckley and Samantha Burnham and Marion Delarue and Yvonne Freund-Levi",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2022",

month = oct,

doi = "10.1002/alz.12512",

language = "English (US)",

volume = "18",

pages = "1832--1845",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "John Wiley and Sons Inc.",

number = "10",

}

TY - JOUR

T1 - Characteristics of subjective cognitive decline associated with amyloid positivity

AU - PREVENT-AD research group

AU - for the Alzheimer's Disease Neuroimaging Initiative

AU - FACEHBI study group

AU - Janssen, Olin

AU - Jansen, Willemijn J.

AU - Vos, Stephanie J.B.

AU - Boada, Merce

AU - Parnetti, Lucilla

AU - Gabryelewicz, Tomasz

AU - Fladby, Tormod

AU - Molinuevo, José Luis

AU - Villeneuve, Sylvia

AU - Hort, Jakub

AU - Epelbaum, Stéphane

AU - Lleó, Alberto

AU - Engelborghs, Sebastiaan

AU - van der Flier, Wiesje M.

AU - Landau, Susan

AU - Popp, Julius

AU - Wallin, Anders

AU - Scheltens, Philip

AU - Rikkert, Marcel Olde

AU - Snyder, Peter J.

AU - Rowe, Chris

AU - Chételat, Gaël

AU - Ruíz, Agustin

AU - Marquié, Marta

AU - Chipi, Elena

AU - Wolfsgruber, Steffen

AU - Heneka, Michael

AU - Boecker, Henning

AU - Peters, Oliver

AU - Jarholm, Jonas

AU - Rami, Lorena

AU - Tort-Merino, Adrià

AU - Binette, Alexa Pichet

AU - Poirier, Judes

AU - Rosa-Neto, Pedro

AU - Cerman, Jiri

AU - Dubois, Bruno

AU - Teichmann, Marc

AU - Alcolea, Daniel

AU - Fortea, Juan

AU - Sánchez-Saudinós, M. Belén

AU - Ebenau, Jarith

AU - Pocnet, Cornelia

AU - Eckerström, Marie

AU - Thompson, Louisa

AU - Villemagne, Victor

AU - Buckley, Rachel

AU - Burnham, Samantha

AU - Delarue, Marion

AU - Freund-Levi, Yvonne

PY - 2022/10

Y1 - 2022/10

N2 - Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. Results: Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Discussion: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.

AB - Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. Results: Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Discussion: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.

KW - Alzheimer's disease

KW - amyloid

KW - cerebrospinal fluid

KW - positron emission tomography

KW - subjective cognitive decline

UR - http://www.scopus.com/inward/record.url?scp=85120831306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120831306&partnerID=8YFLogxK

U2 - 10.1002/alz.12512

DO - 10.1002/alz.12512

M3 - Article

C2 - 34877782

AN - SCOPUS:85120831306

SN - 1552-5260

VL - 18

SP - 1832

EP - 1845

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 10

ER -

Characteristics of subjective cognitive decline associated with amyloid positivity

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this